Systemic immune-inflammation index holds high prognostic value in patients undergoing Bacillus Calmette-Guerin -immunotherapy for bladder cancer

Systemic immune-inflammation index holds high prognostic value in patients undergoing Bacillus Calmette-Guerin -immunotherapy for bladder cancer

Bibliographic Details
Main Authors:	Zhaoxiang Wang, Yuntian Chen, Jiaming Liu, Peng Zhang
Format:	Article
Language:	English
Published:	Elsevier 2022-02-01
Series:	Asian Journal of Surgery
Subjects:	Bladder cancer Non-muscular invasive bladder cancer Systemic immune-inflammation index BCG-Immunotherapy Prognostic value
Online Access:	http://www.sciencedirect.com/science/article/pii/S1015958421007259

Similar Items

Replacement Instead of Discontinuation of Bacillus Calmette-Guérin Instillation in Non-Muscle-Invasive Bladder Cancer
by: Po-Ting Lin, et al.
Published: (2023-02-01)

Successful treatment with low‐dose oral steroids for contracted bladder after intravesical instillation of Bacillus Calmette–Guérin
by: Akinobu Katami, et al.
Published: (2024-03-01)

Bladder Contracture – A Rare and Serious Side Effect of Intravesical Bacillus Calmette-Guérin Therapy
by: Cindy Garcia, et al.
Published: (2016-01-01)

A case of mycotic infrarenal abdominal aortic aneurysm after bacillus Calmette-Guérin immunotherapy for bladder cancer and a review of the literature
by: Vinojan Satchithanantham, MD, FEBVS, FRCSEd, et al.
Published: (2023-09-01)

Intravescical instillation of Calmette-Guérin bacillus and COVID-19 risk
by: Ugo Fedeli, et al.
Published: (2021-02-01)

Drug‐induced interstitial pneumonia after intravesical Bacillus Calmette‐Guerin administration for bladder cancer with scleroderma
by: Fumie Yoshioka, et al.
Published: (2023-03-01)

PD-L1 Expression in High-Risk Non-Muscle-Invasive Bladder Cancer Is Influenced by Intravesical Bacillus Calmette–Guérin (BCG) Therapy
by: Moritz Maas, et al.
Published: (2024-03-01)

Pyuria as a Predictive Marker of Bacillus Calmette–Guérin Unresponsiveness in Non-Muscle Invasive Bladder Cancer
by: Jungyo Suh, et al.
Published: (2021-08-01)

Instillation Strategies for Non-Muscle-Invasive Bladder Cancer in the Bacillus Calmette-Guerin Shortage Era: A Simple Solution for BCG Discontinuation
by: Lin PT, et al.
Published: (2022-11-01)

Optimal interval timing between transurethral resection of bladder tumors and Bacillus Calmette‐Guerin perfusion
by: Tao‐nong Cai, et al.
Published: (2023-12-01)

Seminal papers in urology: maintenance Bacillus Calmette-Guerin (BCG) immunotherapy for recurrent Ta, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized southwest oncology group study (SWOG-8507)
by: Jake Tempo, et al.
Published: (2023-11-01)

Bacillus Calmette–Guérin Immunotherapy for Cancer
by: Fabíola Cardillo, et al.
Published: (2021-05-01)

Similar immune responses to alpha1‐oleate and Bacillus Calmette–Guérin treatment in patients with bladder cancer
by: Shahram Ahmadi, et al.
Published: (2024-04-01)

Impact of intravesical Bacillus Calmette-Guérin and chemotherapy on the bladder microbiome in patients with non-muscle invasive bladder cancer
by: Christopher James, et al.
Published: (2023-04-01)

Efficacy Study of Mitomycin C Pre-infusion in Addition to Periodic Bacillus Calmette-Guerin Infusions in the Management of Non-muscle Invasive Bladder Cancers
by: Deepika Agrawal, et al.
Published: (2021-12-01)

Protective role of Bacillus Calmette–Guérin vaccine in Alzheimer's disease progression: A systematic review and meta-analysis
by: Tungki Pratama Umar, et al.
Published: (2024-03-01)

A Phase 1b Clinical Study of Intravesical Photodynamic Therapy in Patients with Bacillus Calmette-Guérin–unresponsive Non–muscle-invasive Bladder Cancer
by: Girish S. Kulkarni, et al.
Published: (2022-07-01)

Oncolytic and immunotherapeutic CG0070 adenovirus for high-risk bacillus calmette-guerin unresponsive bladder cancer
by: Evan Austin, et al.
Published: (2021-12-01)

Outcomes of intravesical Bacillus Calmette-Guerin in patients with non-muscle invasive bladder cancer: a retrospective study in Australia
by: Chamodi Pillippu Hewa, et al.
Published: (2024-02-01)

Efficacy of Different Bacillus of Calmette-Guérin (BCG) Strains on Recurrence Rates among Intermediate/High-Risk Non-Muscle Invasive Bladder Cancers (NMIBCs): Single-Arm Study Systematic Review, Cumulative and Network Meta-Analysis
by: Francesco Del Giudice, et al.
Published: (2023-03-01)

A Molecular Signature Determines the Prognostic and Therapeutic Subtype of Non-Muscle-Invasive Bladder Cancer Responsive to Intravesical Bacillus Calmette-Guérin Therapy
by: Seon-Kyu Kim, et al.
Published: (2021-02-01)

A case of disseminated M. bovis bacillus Calmette-Guérin (BCG) disease after one month of BCG bladder infusion therapy and analysis of 77 cases of suspected BCG infection in Japan, 2017–2022
by: Masashi Nishimura, et al.
Published: (2023-01-01)

The cuproptosis-associated 11 gene signature as a predictor for outcomes and response to Bacillus Calmette-Guerin and immune checkpoint inhibitor therapies in bladder carcinoma
by: Huiyang Yuan, et al.
Published: (2023-05-01)

Modified Glasgow Prognostic Score as a Predictor of Recurrence in Patients with High Grade Non-Muscle Invasive Bladder Cancer Undergoing Intravesical Bacillus Calmette–Guerin Immunotherapy
by: Matteo Ferro, et al.
Published: (2022-02-01)

A severe Bacillus Calmette-Guérin vertebral osteomyelitis requiring spinal stabilization: a clinical and microbiological investigation
by: Giuliana Carrega, et al.
Published: (2023-06-01)

BCG in Bladder Cancer Immunotherapy
by: Song Jiang, et al.
Published: (2022-06-01)

Granulomatous myocarditis arising from intravesical Bacillus Calmette–Guérin therapy leading to death diagnosed by postmortem examination: a case report
by: Saroja D. Geetha, et al.
Published: (2024-01-01)

Establishment of Three-Dimensional Bioprinted Bladder Cancer-on-a-Chip with a Microfluidic System Using Bacillus Calmette–Guérin
by: Jung Hoon Kim, et al.
Published: (2021-08-01)

Preoperative sarcopenia and systemic immune-inflammation index can predict response to intravesical Bacillus Calmette-Guerin instillation in patients with non-muscle invasive bladder cancer
by: Peng Liu, et al.
Published: (2022-10-01)

Bacillus Calmette-Guerin Increases Base Excision Repair in Bladder Cancer Cells
by: Selçuk Keskin, et al.
Published: (2021-03-01)

Granulomatous Hepatitis Following Intra-Vesical Instillation of Bacillus Calmette–Guérin for Treatment of Bladder Cancer
by: Elsa Alves Branco, et al.
Published: (2021-07-01)

Restaging Transurethral Resection of Bladder Tumours after BCG Immunotherapy Induction in Patients with T1 Non-Muscle-Invasive Bladder Cancer Might not Be Associated with Oncologic Benefit
by: Wojciech Krajewski, et al.
Published: (2020-10-01)

Miliary Tuberculosis Due to BCG Immunotherapy
by: Bilgehan AYGEN, et al.
Published: (1996-03-01)

Recurrence and progression in nonmuscle invasive transitional cell carcinoma of urinary bladder treated with intravesical Bacillus Calmette–Guerin: A single center experience and analysis of prognostic factors
by: Shouki N Bazarbashi, et al.
Published: (2016-01-01)

Delayed Diagnosis of Mycobacterium bovis bacillus Calmette-Guérin Periprosthetic Joint Infection Following Total Knee Arthroplasty
by: Christopher E. Pelt, MD, et al.
Published: (2024-06-01)

A Multi-Gene Signature of Non-Muscle-Invasive Bladder Cancer Identifies Patients Who Respond to Immunotherapies Including Bacillus Calmette–Guérin and Immune Checkpoint Inhibitors
by: Seung-Woo Baek, et al.
Published: (2024-03-01)

Prognostic Role of Preoperative Neutrophil-To-Lymphocyte Ratio (NLR) and Recurrence at First Evaluation after Bacillus Calmette–Guérin (BCG) Induction in Non-Muscle-Invasive Bladder Cancer
by: Junghoon Lee, et al.
Published: (2023-10-01)

Bacillus Calmette-Guérin Spondylodiscitis after Intravesical BCG Therapy: A Case Report
by: Akihito Kawai, et al.
Published: (2022-11-01)

Prognostic Value of Platelet-to-Lymphocyte Ratio in Non-Muscle Invasive Bladder Cancer Patients: Intravesical Bacillus Calmette-Guerin Treatment After Transurethral Resection of Bladder Tumor
by: Ruicheng Wu, et al.
Published: (2022-05-01)

From Interferon to Checkpoint Inhibition Therapy—A Systematic Review of New Immune-Modulating Agents in Bacillus Calmette–Guérin (BCG) Refractory Non-Muscle-Invasive Bladder Cancer (NMIBC)
by: Susanne Deininger, et al.
Published: (2022-01-01)